Type 2 diabetes has become a global epidemic. The World Health Organization expects the number of people affected to double to more than 300 million in the next 20 years. Growing obesity and aging populations are among the principal factors driving the Diabetes epidemic. Over time, diabetes can lead to severe complications throughout the body, making diabetes the 6th leading cause of death in the United States and the leading cause of heart disease.

A comprehensive understanding of the mechanisms underlying diabetes and its complications is fundamental to the development of successful new therapies in this area. Protemix has assembled a team of world-class diabetes experts and has developed significant expertise in the mechanisms of the disease. Moreover the company’s research capitalizes on the 30-year scientific leadership of Protemix’s scientific founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes.

Today, Protemix’s research efforts have resulted in an extensive pipeline of drug candidates that intervene at specific, well-defined targets in diabetes-related disease processes, to rebalance and renormalize key body systems, thus enabling tissue repair and regeneration.